| Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial U Chakravarthy, SP Harding, CA Rogers, SM Downes, AJ Lotery, ... Ophthalmology 119 (7), 1399-1411, 2012 | 932 | 2012 |
| The influence of cost‐effectiveness and other factors on NICE decisions H Dakin, N Devlin, Y Feng, N Rice, P O'Neill, D Parkin Health Economics 24 (10), 1256-1271, 2015 | 283 | 2015 |
| Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set H Dakin, A Gray, R Fitzpatrick, G MacLennan, D Murray, KAT Trial Group BMJ open 2 (1), e000332, 2012 | 205 | 2012 |
| Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database H Dakin Health and quality of life outcomes 11 (1), 151, 2013 | 178 | 2013 |
| “Yes”,“No” or “Yes, but”? Multinomial modelling of NICE decision-making HA Dakin, NJ Devlin, IAO Odeyemi Health Policy 77 (3), 352-367, 2006 | 167 | 2006 |
| A randomised controlled trial of the clinical effectiveness and cost-effectiveness of different knee prostheses: the Knee Arthroplasty Trial (KAT). DW Murray, GS MacLennan, S Breeman, HA Dakin, L Johnston, ... Health technology assessment (Winchester, England) 18 (19), 1, 2014 | 130 | 2014 |
| Patellar resurfacing in total knee replacement: five-year clinical and economic results of a large randomized controlled trial S Breeman, M Campbell, H Dakin, N Fiddian, R Fitzpatrick, A Grant, ... JBJS 93 (16), 1473-1481, 2011 | 115 | 2011 |
| Cost‐minimisation analysis versus cost‐effectiveness analysis, revisited H Dakin, S Wordsworth Health economics 22 (1), 22-34, 2013 | 112 | 2013 |
| A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia E Choy, D Marshall, ZL Gabriel, SA Mitchell, E Gylee, HA Dakin Seminars in arthritis and rheumatism 41 (3), 335-345. e6, 2011 | 108 | 2011 |
| A systematic review and mixed treatment comparison (MTC) of the efficacy of pharmacological treatments for fibromyalgia E Choy, D Marshall, Z Gabriel, S Mitchell, E Gylee, HA Dakin Value in Health 12 (7), A434, 2009 | 108 | 2009 |
| Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement H Dakin, L Abel, R Burns, Y Yang Health and quality of life outcomes 16 (1), 31, 2018 | 100 | 2018 |
| Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre V Kalsi, RB Popat, A Apostolidis, R Kavia, IAO Odeyemi, HA Dakin, ... european urology 49 (3), 519-527, 2006 | 96 | 2006 |
| A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation … U Chakravarthy, SP Harding, CA Rogers, S Downes, AJ Lotery, HA Dakin, ... Health Technology Assessment (Winchester, England) 19 (78), 1, 2015 | 89 | 2015 |
| Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a … S Hopewell, DJ Keene, IR Marian, M Dritsaki, P Heine, L Cureton, ... The Lancet 398 (10298), 416-428, 2021 | 82 | 2021 |
| Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial HA Dakin, S Wordsworth, CA Rogers, G Abangma, J Raftery, SP Harding, ... BMJ open 4 (7), e005094, 2014 | 80 | 2014 |
| Cost‐effectiveness of solvent/detergent‐treated fresh‐frozen plasma GF Riedler, AR Haycox, AK Duggan, HA Dakin Vox sanguinis 85 (2), 88-95, 2003 | 79 | 2003 |
| The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration S Petrou, O Rivero-Arias, H Dakin, L Longworth, M Oppe, R Froud, A Gray Pharmacoeconomics 33 (10), 993-1011, 2015 | 76 | 2015 |
| Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement S Petrou, O Rivero-Arias, H Dakin, L Longworth, M Oppe, R Froud, A Gray Health and quality of life outcomes 13 (1), 106, 2015 | 74 | 2015 |
| Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open‐angle glaucoma and ocular hypertension HA Dakin, NJ Welton, AE Ades, S Collins, M Orme, S Kelly Statistics in medicine 30 (20), 2511-2535, 2011 | 66 | 2011 |
| Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score H Dakin, A Gray, D Murray Quality of Life Research 22 (3), 683-694, 2013 | 65 | 2013 |
alastair grayEmeritus Professor of Health Economics, University of OxfordVerified email at dph.ox.ac.uk
